U.S. Markets closed

CLASS ACTION UPDATE for CGC and PTLA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / January 20, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

Canopy Growth Corporation (CGC)
CGC Lawsuit on behalf of:
investors who purchased September 8, 2017 - November 13, 2019
Lead Plaintiff Deadline: January 21, 2020
Join the action: https://www.zlk.com/pslra-1/canopy-growth-corporation-loss-form?wire=3&prid=5310

The lawsuit alleges: Canopy Growth Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was experiencing weak demand for its softgel and oil products; (2) as a result, the Company would be forced to take a CA$32.7 million restructuring charge due to poor sales, excessive returns, and excess inventory; and (3) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

To learn more about the Canopy Growth Corporation class action, contact jlevi@levikorsinsky.com.

Portola Pharmaceuticals, Inc. (PTLA)
PTLA Lawsuit on behalf of:
investors who purchased November 5, 2019 - January 9, 2020
Lead Plaintiff Deadline: March 16, 2020
Join the action: https://www.zlk.com/pslra-1/portola-pharmaceuticals-inc-loss-form?wire=3&prid=5310

The lawsuit alleges that, during the class period, Portola Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Portola's internal control over financial reporting regarding reserve for product returns was not effective; (2) Portola was shipping longer-dated product with 36-month shelf life; (3) Portola had not established adequate reserve for returns of prior shipments of short-dated product; (4) as a result, Portola was reasonably likely to need to "catch up" on accounting for return reserves; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To learn more about the Portola Pharmaceuticals, Inc. class action, contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/573627/CLASS-ACTION-UPDATE-for-CGC-and-PTLA-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders